BME100 f2013:W900 Group11 L2

BME 100 Fall 2013	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Alvaro Rascon Role(s) Name: Diana Terreros Role(s) Name: John Sherman Role(s) Name: Timothy Millea Role(s) Name: Jesse Morrissey Role(s) Name: student Role(s) LAB 2 WRITE-UP Descriptive Statistics Experiment 1 Dosage (0mg): Mean (3.834); Standard Deviation (1.523010177); Standard Error (0.481618106) Dosage (5mg): Mean (8.932); Standard Deviation (1.593931547); Standard Error (0.504045412) Dosage (10mg): Mean (61.622); Standard Deviation (30.11069386); Standard Error (9.521837451) Dosage (15mg): Mean (657.941); Standard Deviation (212.9429762); Standard Error (67.33848166) Experiment 2 Dosage (0mg): Mean (11.112); Standard Deviation (2.225551617); Standard Error (0.995296941) Dosage (10mg): Mean (10.516); Standard Deviation (7.402885924); Standard Error (3.310671231) Results Experiment 1 Experiment 2 (Please include well-labeled graphs of the results.) Analysis Experiment 1 Tests of the effects of varying LPS doses on rats showed that the drug did not sharply influence Inflammotin levels. At a p-value of 0.86, the data shows that the change in Inflammotin levels were not statistically significant, meaning we cannot prove the slight changes in Inflammotin can be attributed to the LPS dose. Experiment 2 Tests of the effects of varying LPS doses on humans showed sharp increases in Inflammotin levels at increasing LPS doses. Producing a p-value of 1.1E-16, the data has proven that the effect of LPS on Inflammotin in humans is statistically significant for the experiment. The Bonferroni T-Tests produced values below the desired value of 0.008333. (Using inferential statistics, please determine statistically significant differences in the data.) Summary/Discussion In Experiment 1, data concerning the effects of ranging LPS doses on inflammotin levels in rats showed that the drug did not affect inflammotin levels in rats enough to be significant. The average inflammotin levels were increased slightly at the 10mg LPS dose, but with a p-value of 0.86 the effect is not significant enough to prove that the drug was responsible for the very slight increases. In Experiment 2, human subjects with ages ranging from 60-82 showed sharp increases in their Inflammotin levels with increasing LPS doses. With Inflammotin averages increasing tenfold between 10mg and 15mg doses (p-value=6.4824E-08 between 10mg and 15mg), the effect of LPS on Inflammotin levels in humans seems to be statistically significant. (Please discuss the results and statistical analysis from both experiments. State your conclusion.)